EGFR and non-small cell lung carcinoma: The LUX-Lung 3 trial evaluated afatinib versus cisplatin plus gemcitabine or pemetrexed for EGFR-mutation NSCLC patients stratified according to mutation type (exon 19 deletion, L858R, or other) [39].